← Scroll for more →
Aligos Therapeutics, Inc. (ALGS)
Biological Products, (No Diagnostic Substances)
Latest Price
$5.63
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
3.06
P/B Ratio
1.84
Institutional Ownership
36.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 444.1K | $2.0M | 7.12% | -- | 2026-06-30 |
| Alyeska Investment Group, L.P. | 412.0K | $2.0M | 6.61% | -- | 2026-06-30 |
| Sio Capital Management, LLC | 327.2K | $1.0M | 5.25% | -- | 2026-06-30 |
| Marshall Wace, LLP | 246.6K | $1.0M | 3.95% | -20.6K | 2026-06-30 |
| Woodline Partners LP | 177.4K | $1.0M | 2.84% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 175.5K | $1.0M | 2.81% | -2.7K | 2026-06-30 |
| Baker Bros. Advisors LP | 83.1K | -- | 1.33% | -- | 2026-06-30 |
| Hhlr Advisors, Ltd. | 76.2K | -- | 1.22% | -- | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 66.5K | -- | 1.07% | +55.5K | 2026-06-30 |
| UBS Group AG | 60.0K | -- | 0.96% | +22.9K | 2026-06-30 |